Abstract
The circulating ghrelin levels in patients with gastric cancer were lower than in controls. However, there was heterogeneity among results; therefore, studies with larger sample sizes are recommended.
Introduction
Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, largely because it is often asymptomatic until it reaches an advanced stage. Early detection is critical for survival, yet current screening methods can be invasive or lack sensitivity. Ghrelin, a 28-amino acid peptide primarily secreted by the stomach's oxyntic glands, plays a vital role in energy homeostasis and growth hormone secretion. Given its site of origin, researchers have long suspected that gastric malignancies would alter circulating ghrelin levels. However, previous clinical studies yielded conflicting results. This systematic review and meta-analysis aims to resolve these discrepancies and determine the consensus direction of ghrelin changes in GC patients.
Methods
The authors conducted a systematic search across major databases—PubMed, Cochrane Library, EMBASE, and Web of Science—for studies published through November 2022. The study selection process followed a rigorous screening protocol to identify high-quality case-control studies.
Key methodological features included the use of the Newcastle-Ottawa Scale (NOS) for quality assessment and a random-effects model to calculate the Standardized Mean Difference (SMD) with 95% confidence intervals. This model was specifically chosen to account for expected heterogeneity between different study populations and methodologies. Subgroup analyses were also performed based on race (Asian vs. European) and the type of blood sample used (serum vs. plasma).
Key Results
The meta-analysis synthesized data from 9 studies involving a total of 3,196 participants. The pooled data confirmed that circulating ghrelin levels are significantly lower in patients with gastric cancer compared to healthy controls (SMD = -0.255, p < 0.00001).
However, the study found a very high heterogeneity (I² = 88.8%), indicating that nearly 90% of the variation between studies was due to actual differences in study characteristics rather than chance. Subgroup analysis revealed a striking geographic difference: European studies showed a much more pronounced decrease in ghrelin (SMD = -1.279) compared to Asian studies (SMD = 0.062).
To ensure the robustness of these findings, the researchers assessed publication bias. Egger’s test (p = 0.981) suggested no significant publication bias, meaning the results are likely representative of the available research rather than just a reflection of "positive" results being published.
Discussion and Conclusion
The downward trend in ghrelin levels likely stems from gastric atrophy (loss of functional tissue) or the inhibitory effects of Helicobacter pylori infection on ghrelin-producing cells. While this suggests ghrelin's potential as a diagnostic biomarker, several hurdles remain before clinical implementation. The high heterogeneity makes it difficult to set a universal diagnostic cutoff, and the lack of standardized measurement protocols—specifically the use of protease inhibitors during sample collection—can lead to inaccurate measurements.
In conclusion, while circulating ghrelin levels are lower in GC patients, large-scale, multi-center prospective studies using standardized biochemical protocols are required to validate ghrelin as an early-stage screening tool.
Summary updated